CollaStat
Commercial- Indications
- Surgical bleeding
Company intelligence / Profile preview
Dalim Tissen has developed a portfolio of collagen-based medical devices including CollaStat (a hemostatic agent), Collabarrier (an antiadhesion gel), Rapiderm/Rapigraft/Rapi-Gide for wound healing, and cosmeceutical products. CollaStat is CE-marked and used clinically in Korea and internationally. The company has 14 KFDA manufacturing licenses, 4 CE approvals, over 30 patents, and collaborates with leading hospitals such as Asan Medical Center. Clinical results show rapid hemostasis within two minutes during surgery with proven safety in heart/spine operations. International expansion is ongoing through partnerships like Medtronic for global supply.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dalim Tissen Co., Ltd..